# US 2024/0189285 A1 · Composition and method for enhancing mitochondrial biogenesis and activating pgc-1a > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0189285 A1 - Document ID: US20240189285A1 - Status: Published application - Kind: A1 - Application number: 18/586,160 - Filed: 2024-02-23 - Published: 2024-06-13 - Earliest claimed: 2021-08-26 - Assignees: Nanjing Nutrabuilding Bio-Tech Co., Ltd. - Applicants: Nanjing Nutrabuilding Bio-Tech Co., Ltd. - Inventors: Mingru WANG; Ronghua YI; Shawn WELLS; Kylin LIAO - Web page: https://patentgrep.com/patent/US20240189285A1 ## CPC - A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine - A61P 5/00: Drugs for disorders of the endocrine system - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides methods and compounds for enhancing mitochondrial biogenesis in a mammal or for activating PGC-1α in a mammal, comprising administrating to the mammal in need thereof a therapeutically effective amount of L-Ergothioneine, an analog or derivative thereof, or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof (e.g., as an active ingredient). Such administration of L-Ergothioneine is also capable of alleviating mitochondrial dysfunction and boosting cellular function by enhancing mitochondrial biogenesis, and/or promoting health and longevity by improving mitochondrial biogenesis. ## Claims ### Claim 1 A method for enhancing mitochondrial biogenesis in a mammal, comprising administrating to the mammal in need thereof a therapeutically effective amount of L-Ergothioneine, an analog or derivative thereof, or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, as an active ingredient. ### Claim 2 (depends on 1) The method of claim 1, wherein the L-Ergothioneine is administrated to enhance mitochondrial biogenesis by activating PGC-1α. ### Claim 3 (depends on 1) The method of claim 1, wherein the administration of the L-Ergothioneine is configured for alleviating mitochondrial dysfunction, boosting cellular function or promoting health and longevity by enhancing mitochondrial biogenesis. ### Claim 4 (depends on 1) The method of claim 1, wherein the L-Ergothioneine is administrated in an amount ranging from 0.1 μM to 1 M. ### Claim 5 (depends on 4) The method of claim 4, wherein the L-Ergothioneine is administrated in an amount ranging from 0.1 to 500 μM. ### Claim 6 (depends on 1) The method of claim 1, wherein the L-Ergothioneine is prepared in a form of nutritional, drinking, or pharmaceutical composition, for use in a food, drink, nutritional or pharmaceutical products. ### Claim 7 (depends on 1) The method of claim 1, wherein the L-Ergothioneine is administrated as a dietary supplement or an ingredient in a food. ### Claim 8 (depends on 1) The method of claim 1, wherein the L-Ergothioneine is administrated in a form of solutions, liquid suspensions, parenteral solutions, injections, tablets, pills, granules, powder, film, (micro)capsules, aerosols, tonics, syrups, beverages, or nourishments. ### Claim 9 (depends on 1) The method of claim 1, wherein the L-Ergothioneine is administrated orally, by intravenous injection, by intramuscular injection, intraperitoneally or sublingually. ### Claim 10 (depends on 1) The method of claim 1, wherein the L-Ergothioneine is administrated in a daily dose ranging from 0.1 μM to 1 M, or from 0.1 to 500 μM, by a single dose or multiple divided doses. ### Claim 11 A composition for enhancing mitochondrial biogenesis in a mammal, comprising a therapeutically effective amount of L-Ergothioneine, an analog or derivative thereof, or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, wherein the L-Ergothioneine effectively enhances mitochondrial biogenesis. ### Claim 12 (depends on 11) The composition of claim 11, wherein the composition enhances mitochondrial biogenesis by activating PGC-1α. ### Claim 13 (depends on 11) The composition of claim 11, wherein the composition alleviates mitochondrial dysfunction, boosts cellular function or promotes health and longevity by enhancing mitochondrial biogenesis. ### Claim 14 (depends on 10) The method of claim 10, wherein the L-Ergothioneine is in an amount ranging from 0.1 μM to 1 M. ### Claim 15 Use of L-Ergothioneine in manufacturing a composition for enhancing mitochondrial biogenesis in a mammal. ### Claim 16 (depends on 15) The use of claim 15, wherein the L-Ergothioneine enhances mitochondrial biogenesis by activating PGC-1α. ### Claim 17 (depends on 15) The use of claim 15, wherein the L-Ergothioneine alleviates mitochondrial dysfunction, boosts cellular function or promotes health and longevity by enhancing mitochondrial biogenesis. ### Claim 18 (depends on 15) The use of claim 15, wherein the L-Ergothioneine promotes health and longevity by improving mitochondrial biogenesis. ### Claim 19 (depends on 15) The use of claim 15, wherein the L-Ergothioneine is in an amount ranging from 0.1 μM to 1 M. ### Claim 20 (depends on 15) The use of claim 15, wherein the L-Ergothioneine is in a form of solutions, liquid suspensions, parenteral solutions, injections, tablets, pills, granules, powder, film, (micro)capsules, aerosols, tonics, syrups, beverages, or nourishments.